

PRESS RELEASE 28TH Nov 2009: Beremans Ltd announces publication of “Commercial prospects for dengue vaccines”.

Beremans Ltd (www.beremans.com), the Cambridge (UK)-based provider of business intelligence services for the Life Sciences sector, announced today the publication of a report entitled ‘Commercial prospects for dengue vaccines’. Dr. Nicholas Miller, MD of Beremans Ltd, said “This report is a good example of the value of independent analysis. We are not affiliated with or influenced by any organisation with any interest in promoting dengue vaccines, so the report is free from all conflicts of interest. It therefore provides an independent and realistic assessment of the market for dengue vaccines. Furthermore, we believe that it is the only commercially available, highly detailed analysis of the dengue vaccine field”.

As well as summarising the clinical/scientific state of knowledge regarding dengue, the 202-page report also provides an independent assessment of reported global incidence, independently generated estimates of actual global incidence, identification of the main technical challenges associated with dengue vaccine development, and analysis of major stakeholders and their influence on vaccine procurement and pricing. The main candidate dengue vaccines are discussed, pertinent clinical trials are summarised, and the main commercial interests in dengue vaccine development are noted.

The report also presents relevant results from a major exercise to quantify the different populations that might be appropriate for dengue immunisation, namely total populations, urban populations, surviving infant populations, and traveller populations. For traveller populations, this required construction of a detailed model using numerous manipulations, corrections and adjustments of raw travel data. This model provided defensible estimates of actual traveller numbers from each of 21 developed countries to each of >100 countries where dengue transmission may occur. The model was also used to forecast relevant population numbers to 2020, to provide a base for revenue projections.

Importantly, the report identifies key data which lead to rational and defensible assumptions to apply to the model of dengue vaccine revenue projections. These assumptions (e.g. price, time of market entry, maximum market penetration, rate of market penetration, roll-out per country, etc.) are specified and justified in the text, and permit estimation of the market for hypothetical dengue vaccines in (i) the developed world private sector (i.e. a travel vaccine); (ii) the developing world private sector vaccine; and (iii) the developing world public sector. Finally, key experts in the dengue vaccine field were interviewed to obtain third-party views on aspects of dengue vaccines. Full transcripts of these interviews are provided in the report, which contains 31 figures, 45 tables and over 85,000 words.

Dr. Miller said “In our opinion, we have now developed the most comprehensive and accurate model of international travel available. At present, we have only applied it to the dengue vaccine market, because of the importance of dengue and the imminent pivotal clinical trials of dengue vaccines, but our model could be applied to any travel vaccine, or indeed to any product, medical or otherwise, aimed at residents in developed economies travelling to developing or emerging economies. It is a fundamental and valuable resource with very broad applicability.”

For further information please email:

Dr. Nicholas Miller nm01@beremans.com